Breast cancers differ in response to treatment and may have a divergent clinical course despite having a similar histopathological appearance. New technology using DNA microarrays provides a systematic method to identify key markers for prognosis and treatment response by profiling thousands of genes expressed in a single cancer. Microarray profiling of 38 invasive breast cancers now confirms striking molecular differences between ductal carcinoma specimens and suggests a new classification for oestrogen-receptor negative breast cancer. Future approaches will need to include methods for highthroughput clinical validation and the ability to analyze microscopic samples.
Introduction
The decision to provide adjuvant treatment in breast cancer remains a clinical judgement based on classical pathology and surgical staging. The measurement of oestrogen receptor (ER) status is one of a very small number of molecular markers for solid tumours that have a large impact both on estimation of prognosis and the choice of therapy for the individual patient. Despite great efforts to identify better markers, the results in breast cancer have been unimpressive. This may be because many studies have focused on a single gene, protein or pathway. cDNA microarrays, in contrast, offer a systematic method to perform very extensive expression profiling within a single cancer specimen. The enabling technology has been the development of affordable robots that can spot thousands of gene probes onto glass microscope slides in high-density arrays. Fluorescently labelled tumour cDNA and a differently labelled control sample are hybridized together under a cover slip onto the array. The ratio of the two intensities at each spot indicates the relative expression of that gene within the tumour. The technique is suitable for high-throughput analysis and this opens the way for molecular rather than phenotypic taxonomies, which will include new prognostic and treatment response features [1] .
Perou et al use this technology to ask whether novel classifications in breast cancer can be identified from a series of 65 paired and non-paired breast specimens that included 36 ductal carcinomas and 2 lobular carcinomas [2] . Their results underscore the large variability in expression phenotype between individual cancers with the same histology and suggest a new subclassification of ER-negative breast cancer.
Microarray profiles
The analysis of Perou et al used 84 arrays, each containing 8102 probes, producing over 680,000 data points. To make sense of this large data set, the authors used an exploratory analysis tool called two-dimensional hierarchical clustering. In essence, this tool reorders genes and patient samples to reveal new groupings or clusters with similar patterns of gene expression (see Fig. 1 ) [3] . The result is displayed as a dendrogram in which the tumours with the greatest similarity are placed closest together on the tree. Tumours with greater differences are added to more distant nodes and leaves as the ordering process continues. A colour matrix summarizes the magnitude of expression for each gene across the tumours and allows the visual inspection of common expression patterns. The initial clustering examined 1753 genes that showed at least a fourfold change in expression ratio in three or more of the samples. Despite the fact that most of the cases were invasive ductal carcinomas, there was great diversity of gene expression between cases and this involved many different gene groups. This disparity between tumours is perhaps not surprising given the complex genetic and epigenetic changes that occur in breast cancer secondary to loss of normal DNA repair and checkpoint control. However, there was very striking similarity between each of the 22 paired patient samples. Twenty of the pairs were collected before and after doxorubicin-based treatment in a clinical trial of primary medical therapy for advanced breast cancer, and two were synchronous breast primary and lymph node metastasis. The paired samples were consistently clustered together, indicating that, despite the effects of time and chemotherapy treatment, each cancer maintained an expression 'fingerprint'. This conservation of expression is not unique to breast cancer and has also been shown in lymphoma and melanoma samples [4, 5] . However, as shown here, 'fingerprint' clusters may represent the most stable features of the cancer, such as histology or proliferative rate, that can remain constant over many years.
Perou et al then reanalyzed the data to better discriminate between the tumours, taking advantage of the similarity information from the paired tumours. They defined a 'within-between' score to identify genes that showed sig-nificantly greater variation in expression between separate cases as compared to within each pair samples. These scores were then used to recluster the complete set. The reclustering with this 'intrinsic' subset of 496 genes suggested four new breast cancer classifications: ER+ with luminal epithelial cell expression; ER− with basal epithelial expression; Erb-B2+ and ER−/ER low; and normal breast with basal epithelial and adipose cell expression. Most breast cancers arise from luminal ductal epithelium and only 3-15% of cases are thought to arise from basal (myoepithelial) epithelium. The differing origins can be distinguished by examining specific cytokeratins, and the microarray findings were confirmed by performing immunohistochemistry on paraffin material from the parent tumours. This suggestion that ER− cancers may encompass two separate groups is very intriguing, especially as there is some independent evidence that basal epithelial cancers have a worse outcome [6] . Correlation with clinical and outcome data for this series, however, is not yet available, and it is possible that this clustering may not be found in a larger series. Perou et al did, however, identify the same classification by reclustering with a separate set of genes only expressed by epithelial cells (this new set had a 25% overlap with the intrinsic group). It is also likely, given the large size of the data set, that other important patterns will be discovered. Indeed, two-dimensional hierarchical clustering is only one of several mathematical methods that can be used to cluster the data set and has the disadvantage that its agglomerative method can prevent the identification of complex gene relationships.
Conclusion
The validation of gene cluster information presents a key challenge for the best use of microarray data. There is no method at the present time for calculating the significance of a particular cluster prediction. The use of microarray technology is also expensive, both in amount of tumour material required and reagent costs. It will not be feasible for many investigators to extend this approach to very large series to improve correlation with clinical features or predictive value. An alternative approach may be to intensively investigate highly selected sample sets (chosen for different outcome or response to treatment) in order to generate candidate clusters. A minimal set of genes can then be chosen [7] for validation on tissue microarrays [8] . These arrays are pathology slides that contain up to 600 minute paraffin sections, each from a different patient. High-throughput testing can be performed for each candidate marker in a manner analogous to expression arrays, using either immunohistochemistry or fluorescent in situ hybridization. These analyses should ideally be carried out on patient material garnered from prospective, randomized clinical trials so that statistical analysis is based on highquality, independent data.
A disadvantage of profiling macroscopic specimens, as performed in this article, is that gene expression is averaged across all cells in the sample. The authors of the present study highlight the fact that their methods were sensitive enough to detect expression signatures from admixed non-cancer cells. Patterns unique to infiltrating lymphocytes and vascular endothelium, for example, were present as discrete clusters and could be correlated with signatures from lymphocyte and vascular cell lines (Fig. 1) . It is inevitable despite this sensitivity that heterogeneity within the cancer itself will be diluted, which is important because there is considerable variation in chromosomal dosage between breast cancer cells when examined by fluorescent in situ hybridization. Striking changes in copy number can be seen within a single histological section and between primary cancers and their metastases (Gray et al, unpublished data). These dosage changes will give rise to clonal differences in gene expression. Whether distinct subclones within the cancer determine the prognosis will have to be addressed by analyzing microscopic biopsies from laser capture microdissection or fine needle sampling. Robust amplification methods that can preserve RNA expression ratios from such small samples are evolving [9] . It has recently been shown that comparative genome hybridization for chromosomal dosage may be performed at much higher resolution by hybridizing labelled genomic DNA to microarrays (array CGH) [10] [11] [12] , and this is feasible from very small amounts of genomic DNA. Given the inherent variability of expression arrays [13] , combining both techniques for the analysis of microscopic biopsies may offer a more rigorous framework for preliminary analysis of expression data [14] .
Should this new classification of ER-negative cancers become part of the clinical assessment of breast cancer? Not yet, despite the interesting associations found in this work, because there is no independent evidence that new prognostic markers have been identified. We should not, however, have to wait too long for independent corroboration because the number of microarray profiles in the literature will rapidly increase along with the use of tissue microarrays. More fine brushwork should then allow the cancer portraits to reveal their underlying character.
